Background: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from randomized trials ...

Early referral (at <3 months) and early DMARD treatment enable the course of RA to be changed. Once the disease has become aggressive it is much harder to treat and improvements will not be as great ...